Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Gilenya Brain Infection Problems Lead To FDA Warning Label Update August 5, 2015 Irvin Jackson Add Your Comments Federal drug regulators indicate that least two cases of brain infections among Gilenya users have been identified, leading to a warning label update to provide additional information about the potential risks associated with the multiple sclerosis. In a drug safety communication issued on August 4, the FDA warned that one definite case of progressive multifocal leukoencephalopathy (PML) and one likely case of the deadly brain infection were detected in two patients using Gilenya. They are the first confirmed cases of Gilenya brain infections where the user was not also taking another immunosupressant drug previously. As a result of the findings, new information will be addd to the warning label to describe the reported brain infection problems seen with Gilenya. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Progressive multifocal leukoencephalopathy (PML) is an aggressive brain disease that is believed to be caused by the John Cunningham (JC) virus, which has been linked to the use of several different types of medications. The brain infection damages the myelin, or fatty tissue covering the brain, which is needed for proper nerve function in the white matter. The JC virus is usually a harmless virus, but can cause PML in people who have a weakened immune system. Symptoms of PML may include mood changes, confusion, memory loss, weakness on one side of the body and problems walking. In most cases, PML results in severe disability or death, and the FDA is urging patients and healthcare providers to immediately report any potential side effects of Gilenya through the agency’s MedWatch program. The FDA notes a previous case of PML among a Gilenya patient who had not previously taken Tysabri, another MS drug linked to a risk of the brain infection. However, the agency determined that the infection could not be linked conclusively to Gilenya because the patient had taken another immunosupressant drug that could have caused PML. In addition, that patient had taken multiple courses of intravenous corticosteroids that may have caused the infection. The FDA is urging doctors to stop Gilenya treatment immediately if a patient shows any symptoms of PML and to perform a diagnostic evaluation. Concerns About Side Effects of Gilenya Gilenya (fingolimod) was introduced by Novartis for treatment of multiple sclerosis in 2010. It is used to reduce flare-ups and delay the onset of physical disability caused by MS, with approximately 70,000 people throughout the world currently using Gilenya. The FDA fast-tracked approval for the drug through a program designed to allow drug-makers to quickly introduce medications that look promising, despite a lack of testing. However, serious questions have been raised about whether Gilenya and other medications approved through the expedited process were properly vetted. According to a report published last year in the Journal of the American Medical Association (JAMA), Gilenya was cited as an example of a medication that may have been approved too fast. Researchers indicated that at least seven major safety issues were identified during Gilenya clinical trials, including heart problems, liver toxicity, increased risk of infection, reduced pulmonary function, teratogenicity, macular edema and a potentially risk of cancer. Clinical trials involving doses of 5mg and 2.5mg were halted due to safety reasons, leading the FDA to approve Gilenya at the lowest dose possible of 0.5mg. Despite concerns over the safety of Gilenya when it was reviewed, the FDA agreed to fast-track the drug’s approval with only minimal testing because the drug was identified as a crucial medication that addressed needs that were not met by other treatments. In May 2012, the FDA added new Gilenya warnings about the risk of heart problems after a patient died within 24 hours after taking the drug. Doctors were advised not to prescribe Gilenya to patients who have a history of heart problems or who take drugs that lower their heart rates. When the drug is given to patients with heart problems, health regulators indicated that they should be monitored by ECG before the first dose and continuously for six hours afterwards. Amid a substantial number of adverse event reports submitted to the FDA after the Gilenya was approved, the Institute for Safe Medication Practices (ISMP) suggested that the drug should be restricted. The organization of drug safety experts indicated in April 2012 that the FDA should consider restrictions similar to those used on the MS drug Tysabri, which requires close patient monitoring for signs of PML. Tags: Brain Infection, Gilenya, Multiple Sclerosis, Novartis, Progressive Multifocal Leukoencephalopathy (PML) More Lawsuit Stories Depo-Provera Lawsuit Pre-Settlement Funding and Loans Must Be Disclosed Under Court Order July 9, 2025 Judge Extends Deadlines in PFAS Lawsuits Over Liver Cancer, Thyroid Cancer July 9, 2025 Recreational Nitrous Oxide Use Linked to Frostbite Injury Risks, Case Report Warns July 9, 2025 1 Comments Eleanor January 18, 2018 HI,I went into the emergency room with numbness on the left side and was diagnosed with MS in July 2013. I went into a Gilenya case study in August 2013. A month after taking this medication I lost my ability to walk and ended up in a wheel chair, started having seizures, confusion, and fatigue. Two months later I was diagnosed with Uveitis an eye disorder that I never had any problems until I started taking this medication. This medication has ruined my life about time I got off. I continually told the doctor how bad I was feeling and he along his wife who was over the case study and they would tell me to to just wait until the next visit and give me Keppra and pain medicine. The case study was over in August 2015 and the day it was over the doctor and his wife closed and went to Florida. When I received my medical records I found out that blood levels were unstable the whole time and I was unaware. I was about to die!!!!! I never got a chance to ell my story because because it took me about two years to get stable with my MS. After getting stable, I received a diagnoses of breast cancer in December of 2016. I have been struggling with the symptoms I believe that are a result of taking this powerful drug Gilenya and no one is being held accountable for it. I pray that someone would see this post and see that I am in desperate need for help.There is so much more to this story. Thanks for letting my share. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Lawsuit Pre-Settlement Funding and Loans Must Be Disclosed Under Court Order (Posted: today) A U.S. District Judge has ordered women involved in Depo-Provera lawsuits to inform him of any third-party pre-settlement loans they take out, as predatory interest rates may force them to reject settlement offers. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (07/02/2025)Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025) Judge Extends Deadlines in PFAS Lawsuits Over Liver Cancer, Thyroid Cancer (Posted: today) A federal judge has extended deadlines for parties involved in firefighting foam lawsuits to complete discovery and expert reports on liver and thyroid cancer injuries. MORE ABOUT: AFFF LAWSUITPFAS Exposure During Pregnancy Linked to High Blood Pressure in Children: Study (06/26/2025)PFAS Drinking Water Lawsuit Filed by 16 Plaintiffs Over Testicular Cancer, Kidney Cancer, Ulcerative Colitis Side Effects (06/23/2025)AFFF Chemicals May Accelerate Spread of Cancer, Reduce Drug Effectiveness: Study (06/13/2025) Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: yesterday) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Depo-Provera Lawsuit Pre-Settlement Funding and Loans Must Be Disclosed Under Court Order July 9, 2025
Depo-Provera Lawsuit Pre-Settlement Funding and Loans Must Be Disclosed Under Court Order (Posted: today) A U.S. District Judge has ordered women involved in Depo-Provera lawsuits to inform him of any third-party pre-settlement loans they take out, as predatory interest rates may force them to reject settlement offers. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (07/02/2025)Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)
Judge Extends Deadlines in PFAS Lawsuits Over Liver Cancer, Thyroid Cancer (Posted: today) A federal judge has extended deadlines for parties involved in firefighting foam lawsuits to complete discovery and expert reports on liver and thyroid cancer injuries. MORE ABOUT: AFFF LAWSUITPFAS Exposure During Pregnancy Linked to High Blood Pressure in Children: Study (06/26/2025)PFAS Drinking Water Lawsuit Filed by 16 Plaintiffs Over Testicular Cancer, Kidney Cancer, Ulcerative Colitis Side Effects (06/23/2025)AFFF Chemicals May Accelerate Spread of Cancer, Reduce Drug Effectiveness: Study (06/13/2025)
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: yesterday) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)